<DOC>
	<DOC>NCT01775774</DOC>
	<brief_summary>This is a Phase 1, open label, dose escalation, multi-center clinical trial of Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) for the treatment of Acute Respiratory Distress Syndrome (ARDS). The purpose of this study is to assess the safety of hMSCs in patients with ARDS.</brief_summary>
	<brief_title>Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome</brief_title>
	<detailed_description>The primary objective of this study is to assess the safety of intravenous infusion of Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) in patients with ARDS.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<criteria>Patients will be eligible for inclusion if they meet all of the below criteria. Criteria 13 must all be present within a 24hour time period and at the time of enrollment: Acute onset (defined below) of: 1. A need for positive pressure ventilation by an endotracheal or tracheal tube with a PaO2/FiO2 ratio &lt; 200 with at least 8 cm H2O positive endexpiratory airway pressure (PEEP) 2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph 3. No clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates. In addition to meeting inclusion criteria, enrollment must occur within 96hours of first meeting ARDS criteria per the Berlin definition of ARDS. 1. Age less than 18 years 2. Greater than 96 hours since first meeting ARDS criteria per the Berlin definition of ARDS 3. Pregnant or breastfeeding 4. Prisoner 5. Presence of any active malignancy (other than nonmelanoma skin cancer) that required treatment within the last 2 years 6. Any other irreversible disease or condition for which 6month mortality is estimated to be greater than 50% 7. Moderate to severe liver failure (ChildsPugh Score &gt; 12) 8. Severe chronic respiratory disease with a PaCO2 &gt; 50 mm Hg or the use of home oxygen 9. Patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest). 10. Major trauma in the prior 5 days 11. Lung transplant patient 12. No consent/inability to obtain consent 13. Moribund patient not expected to survive 24 hours 14. WHO Class III or IV pulmonary hypertension 15. Documented deep venous thrombosis or pulmonary embolism within past 3 months 16. No arterial line/no intent to place an arterial line 17. No intent/unwillingness to follow lung protective ventilation strategy or fluid management protocol 18. Currently receiving extracorporeal life support (ECLS) or highfrequency oscillatory ventilation (HFOV)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Acute Respiratory Distress Syndrome</keyword>
	<keyword>Acute Lung Injury</keyword>
	<keyword>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells</keyword>
</DOC>